Castrate Resistant Prostate Cancer Clinical Trials

6 recruiting

Castrate Resistant Prostate Cancer Trials at a Glance

13 actively recruiting trials for castrate resistant prostate cancer are listed on ClinicalTrialsFinder across 6 cities in 26 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in Seattle, Jacksonville, and Boston. Lead sponsors running castrate resistant prostate cancer studies include ARTBIO Inc., Epigenetix, Inc., and 858 Therapeutics, Inc..

Browse castrate resistant prostate cancer trials by phase

Treatments under study

About Castrate Resistant Prostate Cancer Clinical Trials

Looking for clinical trials for Castrate Resistant Prostate Cancer? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Castrate Resistant Prostate Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Castrate Resistant Prostate Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting
Phase 1Phase 2

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

Progressive Metastatic Castrate Resistant Prostate Cancer
Novartis Pharmaceuticals188 enrolled29 locationsNCT07206056
Recruiting
Phase 3

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Pfizer600 enrolled233 locationsNCT06551324
Recruiting
Phase 2

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

Prostate CancerProstate CarcinomaMetastatic Castration-resistant Prostate Cancer+1 more
University of California, San Francisco48 enrolled1 locationNCT05766371
Recruiting
Phase 1Phase 2

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Breast CancerOvarian CancerEndometrial Cancer+8 more
858 Therapeutics, Inc.120 enrolled14 locationsNCT06395519
Recruiting
Phase 1

Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Metastatic Castrate Resistant Prostate Cancer (mCRPC)Prostate Cancer (CRPC)
ARTBIO Inc.80 enrolled3 locationsNCT07214961
Recruiting
Phase 2

Dose Optimisation and Prostate-Specific Membrane Antigen (PSMA) Receptor intensification with 177Lu-PSMA Therapy: A Randomised Phase II trial: OPTIMAL-PSMA

Metastatic Castrate Resistant Prostate Cancer (mCRPC)
St Vincent's Health Network120 enrolled1 locationACTRN12625000971437
Recruiting
Phase 1

Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)

Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Jean-Mathieu Beauregard60 enrolled1 locationNCT06943495
Recruiting
Phase 2

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

Metastatic Castrate Resistant Prostate CancerBARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2RAD51B, RAD51C, RAD51D, or RAD54L Mutations
VA Office of Research and Development100 enrolled18 locationsNCT04038502
Recruiting
Phase 1Phase 2

TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors

Renal Cell CancerCastrate Resistant Prostate Cancer
Portage Biotech90 enrolled3 locationsNCT04969315
Recruiting

Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer

Prostate CancerBRCA MutationCastrate Resistant Prostate Cancer
Santa Chiara Hospital3,000 enrolled2 locationsNCT06783127
Recruiting
Phase 1

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

Castrate Resistant Prostate CancerNUT CarcinomaChronic Myelomonocytic Leukemia+1 more
Epigenetix, Inc.75 enrolled6 locationsNCT05488548
Recruiting

Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177Lutetium-PSMA Radioligand Therapy: a Prospective Observational Study - KiRi-Trial

Metastatic Castrate Resistant Prostate Cancer (mCRPC)Kidney DiseaseRadiation Nephropathy
Hannah Schaefer100 enrolled1 locationNCT06720532
Recruiting
Phase 2

Evolocumab in Metastatic Castration-Resistant Prostate Cancer

Metastatic Castrate Resistant Prostate Cancer
National Health and Medical Research Council30 enrolled3 locationsACTRN12622001003763